NYSE:GKOS - Glaukos Stock Price, Price Target & More

$30.33 +0.58 (+1.95 %)
(As of 04/23/2018 11:37 AM ET)
Previous Close$29.75
Today's Range$29.78 - $30.33
52-Week Range$23.08 - $48.89
Volume70,326 shs
Average Volume584,116 shs
Market Capitalization$1.04 billion
P/E Ratio198.33
Dividend YieldN/A
Beta1.05

About Glaukos (NYSE:GKOS)

Glaukos logoGlaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. Glaukos Corporation markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. The company was founded in 1998 and is headquartered in San Clemente, California.

Receive GKOS News and Ratings via Email

Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GKOS
CUSIPN/A
Phone949-367-9600

Debt

Debt-to-Equity RatioN/A
Current Ratio5.58%
Quick Ratio5.16%

Price-To-Earnings

Trailing P/E Ratio198.33
Forward P/E Ratio-79.82
P/E GrowthN/A

Sales & Book Value

Annual Sales$159.25 million
Price / Sales6.63
Cash Flow$0.1595 per share
Price / Cash190.15
Book Value$4.00 per share
Price / Book7.58

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-90,000.00
Net Margins-0.06%
Return on Equity4.03%
Return on Assets3.47%

Miscellaneous

Employees387
Outstanding Shares34,830,000

How to Become a New Pot Stock Millionaire

Glaukos (NYSE:GKOS) Frequently Asked Questions

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

How were Glaukos' earnings last quarter?

Glaukos Corp (NYSE:GKOS) posted its quarterly earnings results on Wednesday, February, 28th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.02. The medical instruments supplier earned $41.65 million during the quarter, compared to the consensus estimate of $40.83 million. Glaukos had a negative net margin of 0.06% and a positive return on equity of 4.03%. The business's revenue was up 25.6% on a year-over-year basis. View Glaukos' Earnings History.

When is Glaukos' next earnings date?

Glaukos is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Glaukos.

What price target have analysts set for GKOS?

8 equities research analysts have issued 12 month price objectives for Glaukos' shares. Their forecasts range from $32.00 to $54.00. On average, they anticipate Glaukos' share price to reach $40.2857 in the next year. View Analyst Ratings for Glaukos.

What are Wall Street analysts saying about Glaukos stock?

Here are some recent quotes from research analysts about Glaukos stock:
  • 1. According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (2/13/2018)
  • 2. Cantor Fitzgerald analysts commented, "Executing Well in a Slightly Adverse Environment. Glaukos reported 37% YoY revenue growth, falling a little short of the 40%+ growth since the launch of iStent slightly more than four years ago (88% of the sales were recorded in the U.S.). The company reported to be on track to have trained >3,000 surgeons by YE17. Glaukos operated in an environment, which was affected by a number of factors: 1: the slow institution of higher reimbursement (challenging during implementation, but favorable afterwards) by commercial payors (20% of total); 2: hurricane-caused delays in surgery ($1 million impact in 3Q17); 3: a negative impact by a single Medicare operator (lowering surgeon’s fees) and by continued sampling and perhaps early sales by competitor Alcon (wholly owned by NVS [Not Covered]). Long term, we believe Glaukos’ iStent has demonstrated significant long-term benefit and cost efficiency to maintain a commercial and competitive advantage. The company remained cautious about 2018, due to the expanded launch by Alcon, a second competitor potentially arriving to the market by 2H18 (Hydrus by Ivantis [private]) and the relatively modest contribution by iStent Inject (PMA to be submitted by YE17). 2018 guidance will be introduced in January at the 4Q17 earnings call." (11/7/2017)

Who are some of Glaukos' key competitors?

Who are Glaukos' key executives?

Glaukos' management team includes the folowing people:
  • Mr. Thomas William Burns, CEO, Pres & Director (Age 57)
  • Mr. Chris M. Calcaterra, Chief Operating Officer (Age 58)
  • Mr. Richard L. Harrison, Advisor (Age 61)
  • Dr. Mory Gharib Ph.D., Co-Founder
  • Mr. Joseph E. Gilliam, CFO & Sr. VP - Corp. Devel.

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Has Glaukos been receiving favorable news coverage?

Press coverage about GKOS stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Glaukos earned a daily sentiment score of 0.00 on Accern's scale. They also gave media headlines about the medical instruments supplier an impact score of 45.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $30.33.

How big of a company is Glaukos?

Glaukos has a market capitalization of $1.04 billion and generates $159.25 million in revenue each year. Glaukos employs 387 workers across the globe.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]


MarketBeat Community Rating for Glaukos (GKOS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  385
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Glaukos (NYSE:GKOS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Glaukos in the last 12 months. Their average twelve-month price target is $40.2857, suggesting that the stock has a possible upside of 32.82%. The high price target for GKOS is $54.00 and the low price target for GKOS is $32.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.883.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $40.2857$41.2857$45.50$49.8333
Price Target Upside: 32.82% upside38.40% upside61.35% upside52.86% upside

Glaukos (NYSE:GKOS) Consensus Price Target History

Price Target History for Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Stifel NicolausDowngradeBuy -> Hold$39.00 -> $32.00HighView Rating Details
3/23/2018Cantor FitzgeraldSet Price TargetBuy$43.00HighView Rating Details
3/23/2018William BlairReiterated RatingOutperformHighView Rating Details
3/1/2018StephensReiterated RatingBuy$36.00HighView Rating Details
3/1/2018BMO Capital MarketsReiterated RatingOutperform -> Outperform$38.00 -> $36.00HighView Rating Details
3/1/2018Canaccord GenuityLower Price TargetBuy$48.00 -> $43.00HighView Rating Details
9/15/2017Piper JaffrayReiterated RatingPositive -> Buy$38.00HighView Rating Details
8/3/2017Roth CapitalLower Price TargetBuy$60.00 -> $54.00HighView Rating Details
10/27/2016Wells FargoInitiated CoverageOutperformN/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Glaukos (NYSE:GKOS) Earnings History and Estimates Chart

Earnings by Quarter for Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20191($0.08)($0.08)($0.08)

Glaukos (NYSE GKOS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018($0.12)N/AView Earnings Details
2/28/2018Q4 2017$0.0090$0.03$40.83 million$41.65 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.02)$0.04$38.69 million$40.41 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.06$0.06$39.88 million$41.29 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.02)$0.02$32.66 million$35.91 millionViewN/AView Earnings Details
3/1/2017Q416$0.0010$0.0040$29.49 million$33.17 millionViewListenView Earnings Details
11/10/2016Q316($0.01)$0.03$27.21 million$29.60 millionViewN/AView Earnings Details
8/1/2016Q216($0.04)$0.06$24.45 million$28.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.15)$0.03$18.77 million$23.10 millionViewN/AView Earnings Details
3/1/2016Q415($0.13)($0.07)$20.07 million$20.28 millionViewN/AView Earnings Details
11/10/2015Q315($0.17)($0.07)$17.93 million$19.00 millionViewListenView Earnings Details
8/12/2015Q2 2015($1.14)($1.30)$15.76 million$17.75 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Glaukos (NYSE:GKOS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Glaukos (NYSE GKOS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.40%
Insider Trading History for Glaukos (NYSE:GKOS)
Insider Trading History for Glaukos (NYSE:GKOS)

Glaukos (NYSE GKOS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2018Orbimed Advisors LlcDirectorSell836,500$32.02$26,784,730.00View SEC Filing  
3/2/2018Jonathan SilversteinDirectorSell464,583$32.29$15,001,385.07View SEC Filing  
11/22/2017Joseph E GilliamCFOBuy2,100$23.84$50,064.00102,100View SEC Filing  
9/7/2017Thomas William BurnsCEOSell73,788$41.36$3,051,871.68View SEC Filing  
9/5/2017Orbimed Advisors LlcDirectorSell580,200$38.73$22,471,146.00View SEC Filing  
9/5/2017Thomas William BurnsCEOSell1,212$41.25$49,995.00View SEC Filing  
8/17/2017Orbimed Advisors LlcDirectorSell325,000$37.93$12,327,250.00View SEC Filing  
3/14/2017Orbimed Advisors LlcDirectorSell382,538$45.33$17,340,447.54View SEC Filing  
2/2/2017Thomas William BurnsCEOSell50,000$42.58$2,129,000.00View SEC Filing  
1/13/2017Chris M CalcaterraInsiderSell18,136$40.01$725,621.36254,413View SEC Filing  
1/13/2017Richard L HarrisonCFOSell20,634$40.00$825,360.0015,709View SEC Filing  
1/9/2017Chris M CalcaterraInsiderSell20,000$38.02$760,400.00260,000View SEC Filing  
1/9/2017Thomas William BurnsCEOSell40,000$37.60$1,504,000.00View SEC Filing  
1/6/2017Richard L HarrisonCFOSell20,634$35.58$734,157.722,656View SEC Filing  
11/17/2016William J Phd LinkDirectorSell30,000$33.78$1,013,400.00View SEC Filing  
11/15/2016Thomas William BurnsCEOSell200,120$33.68$6,740,041.601,388View SEC Filing  
10/24/2016Chris M CalcaterraInsiderSell20,000$36.01$720,200.00260,000View SEC Filing  
10/20/2016Chris M CalcaterraInsiderSell40,000$34.76$1,390,400.00280,000View SEC Filing  
8/12/2016Jonathan SilversteinDirectorSell292,938$33.69$9,869,081.22View SEC Filing  
8/3/2016Orbimed Advisors LlcDirectorSell425,000$30.59$13,000,750.00View SEC Filing  
7/27/2016Richard L HarrisonCFOSell10,000$35.01$350,100.0011,388View SEC Filing  
7/13/2016Thomas William BurnsCEOSell162,254$30.07$4,878,977.781,388View SEC Filing  
7/12/2016Richard L HarrisonCFOSell5,700$30.00$171,000.007,088View SEC Filing  
6/20/2016Richard L HarrisonCFOSell4,300$30.00$129,000.005,688View SEC Filing  
6/20/2016Thomas William BurnsCEOSell7,997$30.00$239,910.001,388View SEC Filing  
6/15/2016Chris M CalcaterraInsiderSell45,464$28.46$1,293,905.44273,600View SEC Filing  
6/6/2016Thomas William BurnsCEOSell24,578$25.16$618,382.481,388View SEC Filing  
6/3/2016Thomas William BurnsCEOSell422$25.00$10,550.001,388View SEC Filing  
6/1/2016Thomas William BurnsCEOSell25,000$23.90$597,500.001,388View SEC Filing  
5/25/2016Thomas William BurnsCEOSell300$25.00$7,500.001,388View SEC Filing  
5/4/2016Chris M CalcaterraInsiderSell74,536$24.40$1,818,678.40245,836View SEC Filing  
5/4/2016Richard L HarrisonCFOSell30,000$24.59$737,700.003,556View SEC Filing  
5/4/2016Thomas William BurnsCEOSell36,700$24.67$905,389.001,388View SEC Filing  
3/4/2016Aimee S WeisnerDirectorBuy2,500$16.03$40,075.00View SEC Filing  
2/25/2016Montreux Equity Partners Iv LpMajor ShareholderSell70,000$16.16$1,131,200.00View SEC Filing  
12/31/2015Richard L HarrisonCFOBuy1,388$15.30$21,236.404,656View SEC Filing  
11/12/2015Aimee S WeisnerDirectorBuy2,500$21.83$54,575.002,500View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Glaukos (NYSE GKOS) News Headlines

Source:
DateHeadline
Glaukos (GKOS) Raised to Strong-Buy at Zacks Investment ResearchGlaukos (GKOS) Raised to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - April 19 at 10:12 PM
Glaukos Corporation to Release First Quarter 2018 Financial Results after Market Close on May 9Glaukos Corporation to Release First Quarter 2018 Financial Results after Market Close on May 9
finance.yahoo.com - April 19 at 5:14 PM
Glaukos (GKOS) Stock Rating Lowered by Zacks Investment ResearchGlaukos (GKOS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:28 AM
Glaukos (GKOS) Downgraded by BidaskClub to "Hold"Glaukos (GKOS) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 18 at 6:22 PM
Piper Jaffray Comments on Glaukos Corps Q1 2019 Earnings (GKOS)Piper Jaffray Comments on Glaukos Corp's Q1 2019 Earnings (GKOS)
www.americanbankingnews.com - April 18 at 8:42 AM
FY2020 EPS Estimates for Glaukos Corp Cut by Analyst (GKOS)FY2020 EPS Estimates for Glaukos Corp Cut by Analyst (GKOS)
www.americanbankingnews.com - April 17 at 7:05 AM
ALNY On Watch, NLNK Exhibits Caution, Keep An Eye On GKOSALNY On Watch, NLNK Exhibits Caution, Keep An Eye On GKOS
www.nasdaq.com - April 16 at 8:43 AM
Glaukos Corporation (GKOS) Reports 2-Yr US IDE Pivotal Trial Results for iStent Inject Show Significant Reductions in ...Glaukos Corporation (GKOS) Reports 2-Yr US IDE Pivotal Trial Results for iStent Inject Show Significant Reductions in ...
www.streetinsider.com - April 16 at 8:43 AM
Glaukos Corporation (GKOS) Reports Filing of Patent Infringement Lawsuit Against Ivantis Inc.Glaukos Corporation (GKOS) Reports Filing of Patent Infringement Lawsuit Against Ivantis Inc.
www.streetinsider.com - April 16 at 8:43 AM
Financial Review: Glaukos (GKOS) versus STRATA Skin Sciences (SSKN)Financial Review: Glaukos (GKOS) versus STRATA Skin Sciences (SSKN)
www.americanbankingnews.com - April 15 at 9:24 PM
IDE Pivotal Trial Results for Glaukos’ iStent inject® Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract SurgeryIDE Pivotal Trial Results for Glaukos’ iStent inject® Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery
finance.yahoo.com - April 14 at 4:49 PM
Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc.Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc.
finance.yahoo.com - April 14 at 8:52 AM
Glaukos (GKOS) Cut to Sell at ValuEngineGlaukos (GKOS) Cut to Sell at ValuEngine
www.americanbankingnews.com - April 13 at 11:10 PM
Roth Capital Cuts Glaukos (GKOS) Price Target to $54.00Roth Capital Cuts Glaukos (GKOS) Price Target to $54.00
www.americanbankingnews.com - April 13 at 5:29 PM
5 Biggest Price Target Changes For Friday5 Biggest Price Target Changes For Friday
www.benzinga.com - April 13 at 5:08 PM
Stifels Doctor Survey Triggers Glaukos DowngradeStifel's Doctor Survey Triggers Glaukos Downgrade
finance.yahoo.com - April 13 at 5:08 PM
Why Glaukos Corp. Is Sinking TodayWhy Glaukos Corp. Is Sinking Today
finance.yahoo.com - April 13 at 5:08 PM
Glaukos (GKOS) Rating Lowered to Hold at Stifel NicolausGlaukos (GKOS) Rating Lowered to Hold at Stifel Nicolaus
www.americanbankingnews.com - April 13 at 10:37 AM
Stifel Downgrades Glaukos Corporation (GKOS) to HoldStifel Downgrades Glaukos Corporation (GKOS) to Hold
www.streetinsider.com - April 13 at 8:58 AM
Zacks: Analysts Anticipate Glaukos Corp (GKOS) Will Announce Quarterly Sales of $38.72 MillionZacks: Analysts Anticipate Glaukos Corp (GKOS) Will Announce Quarterly Sales of $38.72 Million
www.americanbankingnews.com - April 12 at 5:55 AM
Glaukos Corp (GKOS) Given Consensus Recommendation of "Buy" by BrokeragesGlaukos Corp (GKOS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 1:14 PM
Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive ...Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive ...
www.businesswire.com - April 11 at 9:10 AM
 Analysts Anticipate Glaukos Corp (GKOS) to Post -$0.12 EPS Analysts Anticipate Glaukos Corp (GKOS) to Post -$0.12 EPS
www.americanbankingnews.com - April 10 at 1:24 AM
Pre-Market Technical Scan on Medical Supplies Equities -- Daxor, Endologix, Glaukos, and Halyard HealthPre-Market Technical Scan on Medical Supplies Equities -- Daxor, Endologix, Glaukos, and Halyard Health
www.prnewswire.com - April 9 at 8:58 AM
Glaukos (GKOS) Lifted to "Buy" at BidaskClubGlaukos (GKOS) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - April 9 at 1:01 AM
Glaukos (GKOS) Earns Buy Rating from BMO Capital MarketsGlaukos (GKOS) Earns Buy Rating from BMO Capital Markets
www.americanbankingnews.com - April 6 at 5:52 PM
Glaukos (GKOS) Upgraded at ValuEngineGlaukos (GKOS) Upgraded at ValuEngine
www.americanbankingnews.com - April 5 at 1:11 PM
Glaukos (GKOS) Price Target Cut to $40.00 by Analysts at BMO Capital MarketsGlaukos (GKOS) Price Target Cut to $40.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - April 1 at 9:47 AM
Cantor Fitzgerald Analysts Give Glaukos (GKOS) a $48.00 Price TargetCantor Fitzgerald Analysts Give Glaukos (GKOS) a $48.00 Price Target
www.americanbankingnews.com - March 28 at 8:42 PM
Edited Transcript of GKOS earnings conference call or presentation 28-Feb-18 9:30pm GMTEdited Transcript of GKOS earnings conference call or presentation 28-Feb-18 9:30pm GMT
finance.yahoo.com - March 26 at 4:53 PM
Glaukos Corp (GKOS) Expected to Post Quarterly Sales of $38.72 MillionGlaukos Corp (GKOS) Expected to Post Quarterly Sales of $38.72 Million
www.americanbankingnews.com - March 26 at 8:23 AM
Glaukos (GKOS) Downgraded to Sell at ValuEngineGlaukos (GKOS) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 3:47 PM
 Brokerages Expect Glaukos Corp (GKOS) to Post -$0.11 EPS Brokerages Expect Glaukos Corp (GKOS) to Post -$0.11 EPS
www.americanbankingnews.com - March 24 at 1:16 AM
William Blair Reiterates Outperform Rating for Glaukos (GKOS)William Blair Reiterates Outperform Rating for Glaukos (GKOS)
www.americanbankingnews.com - March 23 at 3:28 PM
Glaukos (GKOS) PT Set at $43.00 by Cantor FitzgeraldGlaukos (GKOS) PT Set at $43.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 23 at 1:30 PM
Glaukos Corp (GKOS) Given Average Rating of "Buy" by BrokeragesGlaukos Corp (GKOS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 17 at 1:43 PM
Glaukos Corp (GKOS) to Post FY2018 Earnings of ($0.70) Per Share, Cantor Fitzgerald ForecastsGlaukos Corp (GKOS) to Post FY2018 Earnings of ($0.70) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - March 7 at 11:53 AM
Orbimed Advisors Llc Sells 836,500 Shares of Glaukos Corp (GKOS) StockOrbimed Advisors Llc Sells 836,500 Shares of Glaukos Corp (GKOS) Stock
www.americanbankingnews.com - March 6 at 9:28 PM
Glaukos Corp (GKOS) Director Jonathan Silverstein Sells 464,583 SharesGlaukos Corp (GKOS) Director Jonathan Silverstein Sells 464,583 Shares
www.americanbankingnews.com - March 6 at 9:27 PM
-$0.08 Earnings Per Share Expected for Glaukos Corp (GKOS) This Quarter-$0.08 Earnings Per Share Expected for Glaukos Corp (GKOS) This Quarter
www.americanbankingnews.com - March 6 at 7:17 PM
Glaukos Corp to Post FY2018 Earnings of ($0.69) Per Share, William Blair Forecasts (GKOS)Glaukos Corp to Post FY2018 Earnings of ($0.69) Per Share, William Blair Forecasts (GKOS)
www.americanbankingnews.com - March 5 at 5:38 AM
Glaukos Announces Participation in 30th Annual ROTH ConferenceGlaukos Announces Participation in 30th Annual ROTH Conference
finance.yahoo.com - March 2 at 8:44 AM
Stephens Reaffirms Buy Rating for Glaukos (GKOS)Stephens Reaffirms Buy Rating for Glaukos (GKOS)
www.americanbankingnews.com - March 1 at 6:44 PM
Glaukos (GKOS) Stock Rating Reaffirmed by William BlairGlaukos (GKOS) Stock Rating Reaffirmed by William Blair
www.americanbankingnews.com - March 1 at 5:46 PM
Glaukos (GKOS) PT Lowered to $43.00 at Canaccord GenuityGlaukos (GKOS) PT Lowered to $43.00 at Canaccord Genuity
www.americanbankingnews.com - March 1 at 5:46 PM
BMO Capital Markets Trims Glaukos (GKOS) Target Price to $36.00BMO Capital Markets Trims Glaukos (GKOS) Target Price to $36.00
www.americanbankingnews.com - March 1 at 2:02 PM
Glaukos (GKOS) Issues Quarterly  Earnings ResultsGlaukos (GKOS) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 28 at 7:04 PM
Glaukos Q4 Earnings OutlookGlaukos Q4 Earnings Outlook
finance.yahoo.com - February 28 at 5:37 PM
Glaukos Corporation Announces Fourth Quarter and Full Year 2017 Financial ResultsGlaukos Corporation Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 28 at 5:37 PM
Glaukos Technologies Featured in Numerous Presentations at 2018 American Glaucoma Society MeetingGlaukos Technologies Featured in Numerous Presentations at 2018 American Glaucoma Society Meeting
finance.yahoo.com - February 27 at 5:32 PM

SEC Filings

Glaukos (NYSE:GKOS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Glaukos (NYSE:GKOS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Glaukos (NYSE GKOS) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.